Skip to main content
SpringerLink
Log in

Marrow Replacement Disorders

  • Chapter
  • First Online:
Atlas of Nuclear Medicine in Musculoskeletal System

  • 299 Accesses

Abstract

Disorders of the plasma cells and lymphoid progenitor cells will involve the bone marrow as well as lymphoid tissues. PET/CT utilizing 18F-fluorodeoxyglucose (FDG) is suitable for detection of both intramedullary and extramedullary diseases due to the capability of the FDG PET/CT to survey the whole body and the high FDG uptake demonstrated by most of the aggressive tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

    Article  CAS  Google Scholar 

  2. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lacet Oncol. 2014;15:e538–48.

    Google Scholar 

  3. Kazandjian D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 2016;43(6):676–81.

    Article  Google Scholar 

  4. Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203–23.

    Article  Google Scholar 

  5. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069–75.

    Article  CAS  Google Scholar 

  6. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–7.

    Article  CAS  Google Scholar 

  7. Kumar S, Paiva B, Anderson KC, Durie B, Landgren B, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  Google Scholar 

  8. Terpos E, Dimorpoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16:1223–31.

    Article  CAS  Google Scholar 

  9. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 2009;23(9):1545–56.

    Article  CAS  Google Scholar 

  10. Baur MA, Buhmann S, Becker C, Schoenberg SO, Lang N, Barkl R, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. Am J Roentgenol. 2008;190(4):1097–104.

    Article  Google Scholar 

  11. Zamagni E, Tacchetti, Michele C. Imaging in multiple myeloma: how? When? Blood. 2019;133:644–51.

    Article  CAS  Google Scholar 

  12. Mosebach J, Thierjung H, Schlemmer HP, Stefan D. Multiple myeloma guidelines and their recent updates: implications for imaging. Rofo. 2019;191:998–1009.

    Article  Google Scholar 

  13. Van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systemic review. Cancer. 2012;118:1971–1981.

    Google Scholar 

  14. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013;162:50–61.

    Article  CAS  Google Scholar 

  15. Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica. 2014;99:629–37.

    Article  Google Scholar 

  16. Hameed M, Sandhu A, Soneji N, Amiras D, Rockall A, Messiou C, et al. Pictorial review of whole body MRI in myeloma: emphasis on diffusion-weighted imaging. Br J Radiol. 2020;93:20200312. Epub

    Article  Google Scholar 

  17. Lu YY, Chen JH, Lin WY, Liang JA, Wang HY, Tsai SC, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833–7.

    Article  Google Scholar 

  18. Weng WW, Dong MJ, Zhang J, Yang J, Xu Q, Zhu YJ, et al. A systemic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease – which is best? Asian Pac J Cancer Prev. 2014;15:9879–84.

    Article  Google Scholar 

  19. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–17.

    Article  Google Scholar 

  20. Warsame E, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcome of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87:4468–74.

    Article  Google Scholar 

  21. Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging. 2018;45:77–84.

    Google Scholar 

  22. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  Google Scholar 

  23. Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452–7.

    Article  Google Scholar 

  24. Adams HJ, Nievelstein RA, Kwee TC. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev. 2015;29(6):417–25.

    Article  Google Scholar 

  25. Berthet L, et al. Newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244–50.

    Article  CAS  Google Scholar 

  26. Hong J, Lee Y, Park Y, Kim SG, Hwang KH, Park SH, et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 2012;91(5):687–95.

    Article  CAS  Google Scholar 

  27. Paone G, Itti E, Haioun C, Gaulard P, Dupuis J, Lin C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36(5):745–50.

    Article  Google Scholar 

  28. Lim CY, Ong KO. Imaging of musculoskeletal lymphoma. Cancer Imaging. 2013;13(4):448–57.

    Article  Google Scholar 

  29. Krishnan A, Shirkhoda A, Tehranzadeh J. et-al. Primary bone lymphoma: radiographic-MR imaging correlation. Radiographics. 2003;23(6):1371–83.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

    Joo Hyun O & Ie Ryung Yoo

Authors
  1. Joo Hyun O
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ie Ryung Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ie Ryung Yoo .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea (Republic of)

    Seoung-Oh Yang

  2. Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Korea (Republic of)

    So Won Oh

  3. Department of Nuclear Medicine, Hanyang University College of Medicine, Seoul, Korea (Republic of)

    Yun Young Choi

  4. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (Republic of)

    Jin-Sook Ryu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

O, J.H., Yoo, I.R. (2022). Marrow Replacement Disorders. In: Yang, SO., Oh, S.W., Choi, Y.Y., Ryu, JS. (eds) Atlas of Nuclear Medicine in Musculoskeletal System. Springer, Singapore. https://doi.org/10.1007/978-981-19-2677-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-2677-8_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-2676-1

  • Online ISBN: 978-981-19-2677-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation